Guangdong Taienkang Pharmaceutical Co. Ltd - Asset Resilience Ratio

Latest as of June 2025: 1.60%

Guangdong Taienkang Pharmaceutical Co. Ltd (301263) has an Asset Resilience Ratio of 1.60% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Guangdong Taienkang Pharmaceutical Co. L total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥40.09 Million
≈ $5.87 Million USD Cash + Short-term Investments

Total Assets

CN¥2.51 Billion
≈ $367.06 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2024)

This chart shows how Guangdong Taienkang Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. See Guangdong Taienkang Pharmaceutical Co. L shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Guangdong Taienkang Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Guangdong Taienkang Pharmaceutical Co. L worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥40.09 Million 1.6%
Total Liquid Assets CN¥40.09 Million 1.60%

Asset Resilience Insights

  • Limited Liquidity: Guangdong Taienkang Pharmaceutical Co. Ltd maintains only 1.60% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Guangdong Taienkang Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Guangdong Taienkang Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Guangdong Taienkang Pharmaceutical Co. Ltd (2022–2024)

The table below shows the annual Asset Resilience Ratio data for Guangdong Taienkang Pharmaceutical Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 5.28% CN¥122.10 Million
≈ $17.87 Million
CN¥2.31 Billion
≈ $338.18 Million
-6.01pp
2023-12-31 11.30% CN¥251.80 Million
≈ $36.85 Million
CN¥2.23 Billion
≈ $326.19 Million
-0.50pp
2022-12-31 11.80% CN¥240.65 Million
≈ $35.21 Million
CN¥2.04 Billion
≈ $298.46 Million
--
pp = percentage points

About Guangdong Taienkang Pharmaceutical Co. Ltd

SHE:301263 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.80 Billion
CN¥12.28 Billion CNY
Market Cap Rank
#6678 Global
#1536 in China
Share Price
CN¥28.85
Change (1 day)
+0.70%
52-Week Range
CN¥20.88 - CN¥41.40
All Time High
CN¥41.40
About

Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the… Read more